A comparison of three real-time PCR assays for the confirmation of Neisseria gonorrhoeae following detection of N. gonorrhoeae using Roche COBAS AMPLICOR  by Chui, L. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2008.01950.x
A comparison of three real-time PCR assays for the conﬁrmation
of Neisseria gonorrhoeae following detection of N. gonorrhoeae using
Roche COBAS AMPLICOR
L. Chui1,2, T. Chiu2, J. Kakulphimp2 and G. J. Tyrrell1–3
1Department of Laboratory Medicine and Pathology, University of Alberta, 2Provincial Public Health
Laboratory in Alberta and 3Department of Medical Microbiology and Immunology, University of
Alberta, Edmonton, AB, Canada
ABSTRACT
Three different real-time PCR assays were evaluated as conﬁrmatory tests for Neisseria gonorrhoeae after
initial screening using the COBAS AMPLICOR Chlamydia trachomatis and N. gonorrhoeae duplex assay.
The target genes used for the conﬁrmation were the gyr, cppB and 16S rRNA genes. Analytical speciﬁcity
was determined by testing 60 strains belonging to different bacterial species and ⁄ or serogroups. The
primers chosen from the 16S rRNA gene for conﬁrmation of N. gonorrhoeae were highly speciﬁc, showed
no cross-reactivity with other bacteria included in the study, and had an analytical sensitivity of 1 CFU.
Of 192 clinical specimens that were positive for N. gonorrhoeae according to the COBAS AMPLICOR
assay, 42 were conﬁrmed as positive using the 16S rRNA gene target, 26 were conﬁrmed using the cppB
target, and 30 were conﬁrmed using the gyr target. It was concluded that the real-time PCR assay
targeting the 16S rRNA gene is a useful conﬁrmatory assay to complement the COBAS AMPLICOR
screening test for N. gonorrhoeae.
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INTRODUCTION
Neisseria gonorrhoeae infection is one of the most
prevalent sexually transmitted diseases (STDs)
that affect both genders [1]. Diagnosis of N. gon-
orrhoeae in the early stage of infection can be
difﬁcult, since a signiﬁcant proportion of gono-
coccal infections are asymptomatic or have non-
speciﬁc symptoms [2,3]. It is essential that the
detection methods used can conﬁrm the presence
of the organism so that appropriate antibiotic
therapy can be initiated. Culture is still consid-
ered to be the reference standard for the diagnosis
of N. gonorrhoeae infection. Under optimal labora-
tory conditions, culture has sensitivity in the
range of 85–95% for acute infection [4]. However,
factors such as specimen type and quality, as
well as transport conditions, need to be strin-
gently controlled to achieve this level of sensitiv-
ity, because of the fragility of the organism [5].
Nucleic acid ampliﬁcation tests (NAATs), either
in-house or commercial assays, targetingN. gonor-
rhoeae have been shown to have varying degrees of
speciﬁcity and sensitivity [6–11]. NAATs do not
require viable bacteria, and can therefore circum-
vent the problems of specimen collection and
transportation for this fragile organism, especially
when specimens are collected in remote areas.
A commercial NAAT that is widely used in the
diagnosis of STD is the COBAS AMPLICOR assay;
this is an automated multiplex PCR that detects
both Chlamydia trachomatis and N. gonorrhoeae.
However, a major drawback of this assay with
respect to the detection of N. gonorrhoeae is the
cross-reactivity seen with other Neisseria spp.
[12–15]. To overcome this problem, a conﬁrmatory
assay for N. gonorrhoeae should be used before the
results are reported deﬁnitively [12,16].
The objectives of the present study were to
evaluate the N. gonorrhoeae gyrase (gyr) gene, the
cppB gene located on the N. gonorrhoeae cryptic
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plasmid [17] and the N. gonorrhoeae 16S rRNA
gene as potential genetic targets for conﬁrmation
of an initial positive screening result for N. gon-
orrhoeae according to the COBAS AMPLICOR test,
and to adapt these assays to the real-time Light-
Cycler (LC) platform.
MATERIALS AND METHODS
Bacterial strains and analytical speciﬁcity
The analytical speciﬁcity of the three conﬁrmatory assays was
determined by assaying 60 bacterial strains that were selected
on the basis of being either closely related phylogenetically to
N. gonorrhoeae or present in the urogenital tract. These bacteria
were Actinomyces naeslundii (one clinical isolate), Candida
albicans (ATCC 10231, ATCC 90028), Enterococcus durans
(ATCC 6065), Enterococcus faecalis (ATCC 29212, ATCC
5199), Enterococcus faecium (ATCC 35667), Escherichia coli
(ATCC 25922, ATCC 35218), Fusobacterium nucliatom (ATCC
25586), Gardnerella vaginalis (ATCC 14018), Haemophilus duc-
reyi (one clinical isolate), Lactobacillus confuses (one clinical
isolate), Moraxella catarrhalis (ATCC 25240, ATCC 25238),
Mycoplasma hominis (two clinical isolates), Neisseria cinerea
(ATCC 3308, one clinical isolate), Neisseria ﬂavescens (ATCC
13120), N. gonorrhoeae (ATCC 43069, one clinical isolate),
Neisseria lactamica (ATCC 23970, ATCC 23971), Neisseria
meningitis (ATCC 13102), N. meningitidis serogroup 29E (one
clinical isolate), N. meningitidis serogroup A (one clinical
isolate), N. meningitidis serogroup B (ATCC 13090, one clinical
isolate),N. meningitidis serogroup C (ATCC 13102, one clinical
isolate), N. meningitidis serogroup W135 (two clinical isolates),
N. meningitidis serogroup X (two clinical isolates), N. menin-
gitidis serogroup Y (two clinical isolates), N. meningitidis
serogroup Z (two clinical isolates), Neisseria mucosa (ATCC
19695, one clinical isolate), N. mucosa heidelbergensis (ATCC
25999), Neisseria polysaccharea (AATCC 43768, one clinical
isolate), Neisseria sicca (one clinical isolate), Neisseria subﬂava
(one clinical isolate), N. subﬂava biovar subﬂava ⁄ ﬂava (Roche
6122), N. subﬂava biovar subﬂava ⁄ ﬂava (Roche 6115), N. subﬂava
biovar ﬂava (Roche 6129), Peptostreptococcus sp. (one clinical
isolate), Propionibacterium lymphophilum (ATCC 27520), Propi-
onibacterium sp. (one clinical isolate), Staphylococcus epidermidis
(ATCC 12228, ATCC 14990), Staphylococcus saprophyticus
(ATCC 15305, one clinical isolate), Streptococcus agalactiae
(ATCC 12386), Streptococcus bovis (ATCC 49147, ATCC 9809)
and Vagococcus sp. (one clinical isolate). All of the clinical
isolates were identiﬁed according to phenotypic criteria.
All bacterial cultures were standardised to a 30% transmit-
tance and 200 lL of suspension were used for DNA
extractions.
Analytical sensitivity assays for the three targets
To determine the analytical sensitivity of the three conﬁrma-
tory assays, six strains of N. gonorrhoeae (four clinical isolates
and two reference strains, ATCC 49226 and ATCC 43069)
were standardised to a 30% transmittance and ten-fold
dilutions were made from 10)1 to 10)9. An aliquot of 5 lL
was inoculated in duplicate on chocolate agar plates (Oxoid;
Nepean, Ontario, Canada) and colonies were counted after
incubation for 48 h at 37C to determine the number of
CFU ⁄mL used in the PCR assays. DNA extraction was
performed using 200-lL aliquots of the cell suspensions.
DNA extraction and PCR
DNA was extracted using the automated MagNA Pure LC
instrument (Roche Diagnostics, Laval, Quebec, Canada) in
association with DNA Isolation Kit I (Roche Diagnostics), as
speciﬁed by the manufacturer. Ampliﬁcation using the COBAS
AMPLICOR system was also performed as recommended by
the manufacturer. A 200-lL aliquot of the samples that were
positive according to the COBAS AMPLICOR assay was used
in an extraction with a ﬁnal elution volume of 200 lL; 5-lL
portions of the eluted DNA were then used in the PCR assays
for the gyr, cppB and 16S rRNA genes. Ampliﬁcation of the gyr
and cppB [17] genes was performed in capillaries using the LC
instrument (Roche Diagnostics), with 20-lL reactions contain-
ing 0.5 lM each primer (Table 1), 1 · LC FastStart DNA
Master SYBR Green 1 (Roche Diagnostics), and 2.5 mMMgCl2.
For the PCR targeting the 16S rRNA gene, the ampliﬁcation
mixture contained 1 · LC FastStart DNA Master Hybrid-
ization Probes Reaction Mix (Roche Diagnostics), 0.5 lM each
primer (Table 1), 2.5 mM MgCl2 and 0.2 lM hybridisation
probes in a total volume of 20 lL. A positive control (ATCC
49226) and a negative control (water only) were included in
each LC-PCR run. Primers, probe sequences and ampliﬁcation
conditions are summarised in Table 1.
For specimens that were positive according to the 16S rRNA
gene real-time PCR conﬁrmation assay, DNA sequencing was
performed to conﬁrm that the ampliﬁed product was the
expected gene target. The PCR products were separated by
electrophoresis on agarose 1.5% w ⁄v gels, excised from the
gels and puriﬁed using a QIAquick gel puriﬁcation kit
(Qiagen, Valencia, CA, USA), and then sequenced using an
ABI 3700 sequencer (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions. The
Table 1. PCR primer sequences and conditions for different targets
Target Position Primer and probe sequences PCR conditions
gyr (this study) 168–187
615–635
5¢-ACTGTACGCGATGCACGAGC
5¢-TCGGTTTTGGGTTCGTCCAAA
94C ⁄ 10 min, followed by 45 cycles of 94C ⁄ 10 s, 61C ⁄ 10 s, 72C ⁄ 15 s.
Melting curve: 95C, 51C ⁄ 10 s, increase temperature to 95C at a rate of 0.2C ⁄ s
with continuous acquisition
cppB [17] 3141–3160
3512–3531
5¢-GTCACGCATACCCGCGTTGC
5¢-CGAAGACCTTCGAGCAGACA
94C ⁄ 10 min, followed by 45 cycles of 94C ⁄ 10 s, 45C ⁄ 10 s, 72C ⁄ 15 s.
Melting curve: 95C, 35C ⁄ 10 s, increase temperature to 95C at a rate of 0.2C ⁄ s
with continuous acquisition
16S
rRNA [30]
16S rRNA
probes (this study)
124–144
517–537
440–461
463–478
5¢-TATCGGAACGTACCGGGTAGC
5¢-GTATTACCGCGGCTGCTGGCA
TTGTCAGGGAAGAAAAGGCTGT-FL
LC Red640-GCCAATATCGGCGGCC-PH
95C ⁄ 10 min, followed by 45 cycles of 95C ⁄ 15 s, 59C ⁄ 10 s, 72C ⁄ 17 s.
Melting curve: 95C, 45C ⁄ 20 s, increase temperature to 95C at a rate of 0.2C ⁄ s
with continuous acquisition
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sequences were compared with those for N. gonorrhoeae strain
ATCC 49226 using DNA STAR Megalign software (DNA-
STAR Inc., Madison, WI, USA). The sequences obtained were
also screened against GenBank using BLAST (http://
www.ncbi.nlm.nih.gov/Genbank/GenbankSearch.html) to
conﬁrm that the PCR products were those expected from the
N. gonorrhoeae genes targeted. These samples were further
conﬁrmed using a conventional PCR targeting the orf1 gene
[18], followed by HindIII restriction (PCR–restriction fragment
length polymorphism analysis). The forward and reverse
primer sequences were 5¢-CAACTATTCCCGATTGCGA
(221–239) and 5¢-GTTATACAGCTTCGCCTGAA (461–239),
respectively. The PCR comprised 94C for 10 min, followed
by 45 cycles of 94C for 30 s, 52C for 30 s and 72C for 1 min,
with a ﬁnal extension at 72C for 10 min. Each 50-lL reaction
contained 40 pmol each primer, 100 lMeach dNTP (Invitrogen
Life Technologies, Burlington, Ontario, Canada), 1 U AmpliTaq
Gold (Roche Diagnostics) and 2 lL template. Following ampli-
ﬁcation, 3 lL of the product was subjected toHindIII digestion,
according to the manufacturer’s speciﬁcation, and was then
analysed by electrophoresis on agarose 2% w ⁄v gels.
Clinical specimens
The clinical samples were collected from patients attending the
Sexually Transmitted Disease Clinics or Family Planning
Clinics in Edmonton, Alberta, Canada between 1 January
2003 and 30 June 2004. Urine from males was collected in
sterile containers, while cervical swabs from females were
inserted in dry collection tubes; both types of specimen were
transported to the laboratory at room temperature. Upon
receipt in the laboratory, urine samples were vortexed and a
200-lL aliquot of the supernatant was used for DNA extraction
in the MagNA Pure LC instrument. Cervical swabs were
inserted into 1 mL of sterile saline, vortexed and then removed
from the tube, after which 200 lL was used for extraction, as
for the urine samples. For each sample processed, the internal
control provided in the COBAS AMPLICOR kit was added to
the reaction mixture and was co-ampliﬁed with the target
DNA to monitor potential inhibition. Positive and negative
controls supplied by the manufacturer, as well as in-house
positive and negative controls, were included in each run.
For the COBAS AMPLICOR assay, results were interpreted
according to the product insert. An optical density at A660 of
‡0.2 units was interpreted as a presumptive positive result. If
the IC and the N. gonorrhoeae target A660 values were <0.2, the
assay was interpreted as showing inhibition; in such instances,
the test was repeated after diluting specimens 1:10. Collection
of a follow-up specimen was requested if the repeated test still
showed evidence of inhibition. According to the algorithm
established in the laboratory at the time of the comparison
study, all samples that were positive according to the COBAS
AMPLICOR assay were re-extracted within 24 h and con-
ﬁrmed using a different gene target. This protocol also
included an extra step involving cross-checking by two
laboratory assistants to ensure that the correct specimen was
identiﬁed for conﬁrmation. During the validation period of
1.5 years, all specimens that were positive for N. gonorrhoeae
according to the COBAS AMPLICOR assay were tested by
real-time PCR for the gyr, cppB and 16S rRNA gene targets, as
well as by the standard laboratory conﬁrmation assay using
PCR in a 96-well format and probe hybridisation for the 16S
rRNA with the primers and probes provided by Roche
Diagnostics. A positive N. gonorrhoeae result was determined
by comparing the melting temperature in the SYBR Green
assays (gyr and cppB real-time PCRs) with the positive control;
a positive result was recorded for the real-time 16S rRNA
assay on the basis of an analysis of the ampliﬁcation curve and
the melting temperature.
Statistical analysis
Differences among the results obtained using the 16S rRNA
gene, the gyr gene and the cppB gene as the target were
analysed using the McNemar method.
RESULTS
Analytical speciﬁcity
The COBAS AMPLICOR assay for N. gonorrhoeae
cross-reacted with N. subﬂava biovar subﬂava ⁄ ﬂava
and N. subﬂava biovar ﬂava. N. mucosa and
N. mucosa heidelbergensis were also misidentiﬁed
asN. gonorrhoeaewhen the N. gonorrhoeae gyr gene
was the target in the conﬁrmatory assay and
melting temperature was used for the analysis.
The melting temperatures using the positive con-
trol strains of N. gonorrhoeae were 88C and 86C
for the gyr and cppB genes, respectively, with ±1C
tolerance for themelting curves in both assays. The
melting temperatures for N. mucosa, N. mucosa
heidelbergensis and N. gonorrhoeae were 88–89C,
and the sizes of the gyr amplicons from these
isolates were identical when analysed using aga-
rose gel electrophoresis. Sequencing revealed that
there was >90% homology between the amplicons
for N. gonorrhoeae and N. mucosa, but only 35%
homology for N. gonorrhoeae and N. mucosa heidel-
bergensis. No misidentiﬁcations were obtained
with primers targeting the cppB and 16S rRNA
genes for any of the bacterial strains assayed.
Detection of 16S rRNA gene amplicons used a
hybridisation probe, but the melting curve was
always checked for conﬁrmation. The melting
temperature of all positive samples was 60 ± 1C,
with a cycle cut-off (Ct) value of 36 cycles.
Analytical sensitivity
The detection limit for the COBAS AMPLICOR
assay was 10 CFU ⁄mL, while that for detection of
the gyr gene by LC PCR was 100 CFU ⁄mL. Both
the cppB and 16S rRNA LC assays had a detection
limit of 1 CFU ⁄mL, and were ten-fold and 100-
fold more sensitive than the COBAS AMPLICOR
and gyr assays, respectively.
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Clinical specimens
Of 7731 clinical specimens that were screened
using the COBAS AMPLICOR assay, 192 (2.5%),
comprising 156 swabs and 36 urine samples, were
positive according to the manufacturer’s criteria.
These samples were further analysed using the
three LC conﬁrmatory assays targeting the gyr,
cppB and 16S rRNA genes of N. gonorrhoeae. The
number of positive PCR results conﬁrmed using
the different targets, together with the corre-
sponding A660 values from the COBAS AMPLI-
COR assay, are summarised in Table 2. In total, 32
of the 42 samples that were positive according to
the 16S rRNA gene PCR were conﬁrmed by at
least one of the other conﬁrmatory PCR assays
(gyr or cppB). The remaining ten samples were
only conﬁrmed as N. gonorrhoeae according to the
16S rRNA assay; the Ct values for these ten
samples are shown in Table 3, with an average Ct
value for these samples of 28.48. The ampliﬁed
products were puriﬁed, sequenced and checked
against sequences contained in GenBank, and
were also conﬁrmed using PCR to amplify the orf1
gene. The latter yielded a PCR product of 260 bp
(Fig. 1a), which generated two fragments of 107
and 153 bp following digestion with HindIII
(Fig. 1b).
Two specimens conﬁrmed as N. gonorrhoeae-
positive according to PCR for the cppB and 16S
rRNA genes, but not according to PCR for the gyr
gene, had A660 values in the COBAS AMPLICOR
assay of >3.5. Twenty-four of the 42 samples were
conﬁrmed asN. gonorrhoeae-positive by PCR for all
three targets; each of these had anA660 value in the
COBAS AMPLICOR assay of >3.5. Six (14%)
specimens were conﬁrmed as positive according
to PCR for the gyr and 16S rRNA genes, but not
according to PCR for the cppB gene; this result is in
line with the ﬁndings of earlier studies of N. gon-
orrhoeae isolates from the same STD population,
which indicated that 12% of isolates lacked the
cppB cryptic plasmid (L. Chui, J. Kakulphimp and
W. Albritton, unpublished results). However,
overall, there were signiﬁcant differences in the
conﬁrmation of N. gonorrhoeae-positive specimens
according to PCRs targeting the 16S rRNA gene
and the gyr (p <0.001) and cppB (p <0.001) genes.
DISCUSSION
All of the clinical specimens included in this
study were initially assayed by the COBAS
Table 2. Correlation of optical density (OD) values gen-
erated with the COBAS AMPLICOR assay and positive
results obtained according to PCRs for different targets
COBAS
AMPLICOR
OD values
Total no. of
specimens gyr cppB 16S rRNA
>0.2–2.0 94 1 0 1
>2.0–3.5 32 1 0 3
>3.5 66 28 26 38
Total 192 30 26 42
Table 3. Crossing point (Ct) values for ten specimens
conﬁrmed as positive only by the 16S rRNA gene assay
Specimen no. Type of specimen Real-time PCR Ct value
a
3389 Swab 32.30
5077 Swab 30.14
5758 Swab 26.54
3772 Swab 30.68
7636 Urine 23.83
4615 Urine 27.80
5224 Urine 35.66
4150 Urine 28.12
1143 Urine 26.18
7091 Urine 23.72
aThe Ct value is the number of cycles after which the real-time PCR indicated a
positive result.
(a)
(b)
Fig. 1. (a) Ampliﬁed products (260 bp) generated by PCR
using the orf1 gene as target. (b) HindIII fragments (107 bp
and 153 bp) generated from the PCR products shown in
(a). Lanes: 1, 8 and 15, 100-bp marker; 2–7 and 9–12, clinical
isolates; 13, Neisseria gonorrhoeae positive control strain
ATCC 49226; 14, negative control (water).
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AMPLICOR duplex assay for C. trachomatis and
N. gonorrhoeae. This assay has been validated for
urethral and endocervical swabs and for urine
specimens, with sensitivities of 92.4–100% for
swabs and of 42.3–94.1% for urine, and with
speciﬁcities of 95.9–99.9% for all three types of
specimen [8,9,13,15,19–23]. However, a major
drawback of this assay is its reported cross-
reactivity with other Neisseria spp. and lactobacilli
[5,12,14,20,21]. The present study provides further
evidence of this continuing problem.
To address this problem, an alternative algo-
rithm, designed to expand the equivocal zone for
the COBAS AMPLICOR assay, that increases the
speciﬁcity of the assay has been proposed [9,21]. In
a multicentre trial using an expanded equivocal
zone [21], it was observed that 53% of the speci-
mens with A660 values of 0.2–3.5 were negative
according to the 16S rRNA LC assay. Using the
same approach, the present study found that only
42 (22%) of 192 positive sampleswere conﬁrmed as
positive for N. gonorrhoeae according to two of the
three real-time conﬁrmation assays tested, by orf1
gene PCR–restriction fragment length polymor-
phism, or by sequencing the ampliﬁed 16S rRNA
PCR products.When the expanded equivocal zone
was applied, 57.5% (38 ⁄ 66) of the samples with
A660 values >3.5 were conﬁrmed according to 16S
rRNA PCR, 9.4% (3 ⁄ 32) with values >2.0–3.5, and
1.1% (1 ⁄ 94) with values >0.2–2.0. Therefore, the
majority of the conﬁrmed positive samples had
A660 values >3.5. This ﬁnding is in accord with
previous studies [5,14,16,21]. Based on the results
of the present study, if the original cut-off A660
value of 0.2 recommended by the manufacturer
was used, 2.5% (192 ⁄ 7731) of the samples would
have been identiﬁed as positive for N. gonorrhoeae,
compared with 0.54% (42 ⁄ 7731) based on positive
results with at least two PCR conﬁrmation assays
or PCR and sequencing of the ampliﬁed products.
There was also 100% concordance between the 16S
rRNA gene LC assay and the established standard
conﬁrmation assay using the 16S rRNA gene target
provided by Roche Diagnostics (results not
shown).
When multi-assay consensus was used as the
criterion for N. gonorrhoeae conﬁrmation, 14% of
the samples that were positive according to
COBAS AMPLICOR were conﬁrmed by the gyr
and 16S rRNA LC assays, but gave a negative
result with primers targeting the cryptic plasmid
cppB gene. A failure to amplify the cppB gene has
been documented in previous studies [12,14,24–
26]. In one study [12], 5.7% of positive N. gonor-
rhoeae clinical samples collected in The Nether-
lands failed to yield a cppB amplicon, and 5.8% of
N. gonorrhoeae isolates from patients in Amster-
dam also showed this characteristic [24]. How-
ever, cppB-negative strains were distributed
unevenly throughout The Netherlands, suggest-
ing that N. gonorrhoeae isolates lacking the cppB
gene may be associated with particular patient
populations [12]. Palmer et al. [14] demonstrated
that 18 of 20 N. gonorrhoeae isolates of the PAU
auxotype, which are typically plasmid-free strains
[27], could not be detected by PCR targeting the
cppB gene. Other studies have revealed that the
cppB gene is not only found in the cryptic plasmid
[28], but is also integrated into the chromosome of
some strains [25,29]. Chromosomal integration of
the cppB gene was the rationale that supported the
use of the cppB gene as a target for detecting
N. gonorrhoeae. However, the present study, as
well as previous studies, revealed that signiﬁcant
numbers of isolates do not possess this target, and
the cppB gene can therefore not be recommended
for use as a target in the conﬁrmation of N. gon-
orrhoeae [12,14,24].
False-positive results have also been observed
when using the cppB gene as a target, and these
have been attributed to cross-reactions with
N. cinerea, N. ﬂavescens, N. lactamica, N. subﬂava
and N. sicca [14]. Homology has been observed
between the cryptic plasmid of N. gonorrhoeae and
plasmids in other Neisseria spp. [14]. Neverthe-
less, although these species were included in the
present study, no ampliﬁed cppB DNA was
detected. Similarly, the gyr gene would not be
the target of choice for N. gonorrhoeae, because of
cross-reactions with N. mucosa and N. mucosa
heidelbergensis. The gyr LC assay had the least
sensitivity of the assays tested. It was not possible
to explain why the ten samples that were positive
only according to the 16S rRNA assay were not
detected by the gyr assay, but a possible explana-
tion might be a change in the sequence of the gyr
gene target. According to McNemar analysis,
there was a signiﬁcant difference (p <0.001)
between the results obtained using the 16S rRNA
and gyr assays. Similarly, there was a signiﬁcant
difference (p <0.001) between the results obtained
using the 16S rRNA and cppB assays.
On the basis of these results, the COBAS
AMPLICOR C. trachomatis ⁄N. gonorrhoeae assay
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can be used as a preliminary screening test for
N. gonorrhoea, provided that positive results are
conﬁrmed using the 16S rRNA assay. By using
the MagNa Pure LC instrument, DNA can be
extracted from clinical specimens and ampliﬁed
on an LC platform with minimal handling. The
16S rRNA LC PCR assay was more sensitive and
speciﬁc than the gyr and cppB LC assays, and the
entire conﬁrmation process can be completed
within 10 h.
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